Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine
Ad26.COV2.S 코비드-19 백신의 1-2a상 시험 중간 결과
Clinical Trial
[키워드] acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
Ad26
Ad26.COV2.S
Ad26.COV2.S vaccine
Adenovirus
administration
adverse event
age
All participants
Antibody Response
assigned
authority
candidate vaccine
CD4+ T-cell
CD8+ T-cell
Cohort
cohorts
collected
coronavirus
coronavirus disease
Coronavirus disease 2019
COV1001
COV2.S
Department
development
dose
Factor
fatigue
Fever
full-length
geometric mean
geometric mean titer
GMT
headache
healthy
High dose
Human
increase in
Infection
Injection-site pain
Interim
Johnson & Johnson
less
low dose
milliliter
multicenter
myalgia
Neutralizing-antibody
Neutralizing-antibody titers
Older
pandemic
participant
phase
Placebo
placebo-controlled
primary end point
profile
provided
Randomly
reached
reactogenicity
receive
regimen
remained
reported
research and development
respiratory
response
responses
Result
robust
SARS-CoV-2
SARS-CoV-2 spike protein
second dose
serotype
severe acute respiratory syndrome Coronavirus
Spike protein
Support
systemic
systemic adverse events
T cells
T-cell responses
titer
titers
Trial
two-dose regimen
type 1 helper
Vaccine
vaccine candidate
vaccine dose
Viral
viral particle
wild-type virus
[DOI] 10.1056/NEJMoa2034201 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1056/NEJMoa2034201 PMC 바로가기 [Article Type] Clinical Trial